NRG Oncology CC001: A phase III trial of hippocampal avoidance (HA) in addition to whole-brain radiotherapy (WBRT) plus memantine to preserve neurocognitive function (NCF) in patients with brain metastases (BM). Other Scholarly Work

Gondi, Vinai, Deshmukh, Snehal, Brown, Paul D et al. (2019). NRG Oncology CC001: A phase III trial of hippocampal avoidance (HA) in addition to whole-brain radiotherapy (WBRT) plus memantine to preserve neurocognitive function (NCF) in patients with brain metastases (BM). . JOURNAL OF CLINICAL ONCOLOGY, 37(15), 10.1200/JCO.2019.37.15_suppl.2009

International Collaboration

cited authors

  • Gondi, Vinai; Deshmukh, Snehal; Brown, Paul D; Wefel, Jeffrey Scott; Tome, Wolfgang; Armstrong, Terri; Bruner, Deborah; Bovi, Joseph A; Robinson, Cliff Grant; Khuntia, Deepak; Grosshans, David R; Konski, Andre A; Roberge, David; Kundapur, Vijayananda; Devisetty, Kiran; Shah, Sunjay A; Usuki, Kenneth; Anderson, Bethany Marie; Mehta, Minesh P; Kachnic, Lisa A

sustainable development goals

authors

publication date

  • May 20, 2019

webpage

published in

keywords

  • Life Sciences & Biomedicine
  • Oncology
  • Science & Technology

Location

  • Chicago, IL

Digital Object Identifier (DOI)

publisher

  • AMER SOC CLINICAL ONCOLOGY

volume

  • 37

issue

  • 15